Mini-dose esketamine–dexmedetomidine combination to supplement analgesia for patients after scoliosis correction surgery: a double-blind randomised trial
Primary resultResult — go to the resultRelative risk 0.76 95% CI 0.65–0.90Authors' conclusion
The mini-dose esketamine-dexmedetomidine combination safely improved analgesia and subjective sleep quality after scoliosis correction surgery.
Study context
- Population
- Adults having scoliosis correction surgery199 ITT analysed
- Participants
- Two hundred adults
- Comparison
- Sufentanil PCA with esketamine–dexmedetomidine supplement vs placebo
- Combined supplementn = 99
- Placebon = 100reference
- Primary endpoint
- Incidence of moderate-to-severe pain (NRS ≥4 at any of seven time points)
- Follow-up
- 72 h
Methodological detailsdouble-blind, placebo-controlled, Mean infusion rates 5.5 μg kg-1 h-1 esketamine and 0.02 μg kg-1 h-1 dexmedetomidine
- Double-blind
- Placebo-controlled
- Mean infusion rates 5.5 μg kg-1 h-1 esketamine and 0.02 μg kg-1 h-1 dexmedetomidine
Primary result
As reported in the abstract
Relative risk
0.76
95% CI 0.65–0.90
P = 0.001
Events by treatment group
Combined supplement vs Placebo
RR 0.76 (95% CI 0.65–0.90); P = 0.001
Secondary outcomes
| Outcome | Estimate | P value |
|---|---|---|
| Pain intensity at rest (five time points) | median difference −1 point | P ≤ 0.005 |
| Pain intensity with movement (six time points) | median difference −1 point | P ≤ 0.001 |
| Subjective sleep quality (NRS) · first 5 postoperative nights | median difference −2 to −1 points | P < 0.001 |
Safety
Adverse events
- Did not differ between groups
Original publication
Mini-dose esketamine–dexmedetomidine combination to supplement analgesia for patients after scoliosis correction surgery: a double-blind randomised trial. Br J Anaesth. Published 9 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →